Business
NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives
CARMEL, Ind., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced new medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing approximately 566,000 total covered lives, in Michigan. With this addition, approximately 82% of commercially insured pediatric ben
About this update from Neuraxis, Inc.
[{"type":"image","alt":"NeurAxis, Inc.","displaySize":"","headline":null,"caption":"NeurAxis, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/53c594c0241aa2985511c98a9154c355"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/26D4nWOeQUW1.Tx0Xl.qeg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/53c594c0241aa2985511c98a9154c355","width":300,"height":89}},"lazy":false},{"type":"text","content":"CARMEL, Ind., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced new medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing approximately 566,000 total covered lives, in Michigan. With this addition, approximately 82% of commercially insured pediatric beneficiaries in Michigan now have access to PENFS under medical policy. This expansion increases NeurAxis’ total national coverage to roughly 55 million total lives, with additional payer decisions from major insurers expected in the coming months.","length":746,"tagName":"p"},{"type":"text","content":"NeurAxis’ proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia (nausea symptoms) in patients 8 years and older. IB-Stim is a non-invasive neuromodulation device that gently stimulates cranial nerve bundles in the ear to help regulate pain signaling between the gut and the brain. Currently, no FDA-approved drug therapies exist for pediatric patients with abdominal pain-related disorders of gut-brain interaction (DGBIs), a significant unmet medical need. In the absence of approved options, off-label prescription drugs are often used, despite limited efficacy data and potential safety concerns—underscoring IB-Stim’s unique position as the only FDA-cleared therapy specifically designed for this large and underserved pain related patient population.","length":874,"tagName":"p"},{"type":"text","content":"“We remain focused on expanding insurance coverage for IB-Stim to make this much-needed therapy for abdominal pain assoc...